Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1969 1
1970 1
1973 1
1978 1
1980 3
1981 2
1982 5
1983 1
1984 2
1985 3
1986 2
1987 4
1988 2
1989 10
1990 7
1991 7
1992 6
1993 9
1994 12
1995 8
1996 11
1997 7
1998 10
1999 3
2000 7
2001 9
2002 12
2003 15
2004 11
2005 19
2006 11
2007 16
2008 28
2009 23
2010 21
2011 27
2012 32
2013 25
2014 32
2015 28
2016 21
2017 15
2018 22
2019 31
2020 32
2021 24
2022 23
2023 21
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

567 results

Results by year

Filters applied: . Clear all
Page 1
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. N Engl J Med. 2022. PMID: 35139274 Clinical Trial.
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
O'Shaughnessy J, Sousa S, Cruz J, Fallowfield L, Auvinen P, Pulido C, Cvetanovic A, Wilks S, Ribeiro L, Burotto M, Klingbiel D, Messeri D, Alexandrou A, Trask P, Fredriksson J, Machackova Z, Stamatovic L; PHranceSCa study group. O'Shaughnessy J, et al. Eur J Cancer. 2021 Jul;152:223-232. doi: 10.1016/j.ejca.2021.03.047. Epub 2021 Jun 16. Eur J Cancer. 2021. PMID: 34147014 Free article. Clinical Trial.
Surveillance imaging in pediatric lymphoma.
Voss SD, Cairo MS. Voss SD, et al. Among authors: cairo ms. Pediatr Radiol. 2019 Oct;49(11):1565-1573. doi: 10.1007/s00247-019-04511-4. Epub 2019 Oct 16. Pediatr Radiol. 2019. PMID: 31620855 Review.
Immunotherapeutic Challenges for Pediatric Cancers.
Hutzen B, Ghonime M, Lee J, Mardis ER, Wang R, Lee DA, Cairo MS, Roberts RD, Cripe TP, Cassady KA. Hutzen B, et al. Among authors: cairo ms. Mol Ther Oncolytics. 2019 Aug 28;15:38-48. doi: 10.1016/j.omto.2019.08.005. eCollection 2019 Dec 20. Mol Ther Oncolytics. 2019. PMID: 31650024 Free PMC article. Review.
New frontiers in pediatric Allo-SCT.
Talano JM, Pulsipher MA, Symons HJ, Militano O, Shereck EB, Giller RH, Hancock L, Morris E, Cairo MS. Talano JM, et al. Among authors: cairo ms. Bone Marrow Transplant. 2014 Sep;49(9):1139-45. doi: 10.1038/bmt.2014.89. Epub 2014 May 12. Bone Marrow Transplant. 2014. PMID: 24820213 Free PMC article. Review.
567 results